Literature DB >> 11121762

The role of the CFTR in susceptibility to Pseudomonas aeruginosa infections in cystic fibrosis.

J B Goldberg1, G B Pier.   

Abstract

Recent molecular and cellular studies have shed new light on the basis for the susceptibility of cystic fibrosis (CF) patients to Pseudomonas aeruginosa infection. Changes in airway liquid composition and/or viscosity, enhanced bacterial binding to mucin and epithelial cell receptors, increased innate inflammation owing to disruptions in lipid metabolism and a role for the CFTR protein in bacterial ingestion and clearance have all been postulated. The high P. aeruginosa infection rate in CF patients can potentially be explained by the specificity of the interaction between the CFTR and P. aeruginosa.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11121762     DOI: 10.1016/s0966-842x(00)01872-2

Source DB:  PubMed          Journal:  Trends Microbiol        ISSN: 0966-842X            Impact factor:   17.079


  23 in total

Review 1.  Recognition of mucin components by Pseudomonas aeruginosa.

Authors:  R Ramphal; S K Arora
Journal:  Glycoconj J       Date:  2001-09       Impact factor: 2.916

2.  Cystic fibrosis presenting with corneal perforation and crystalline lens extrusion.

Authors:  Danielle S Hall; Saurabh Goyal
Journal:  J R Soc Med       Date:  2010-07       Impact factor: 5.344

3.  Evolutionary analysis of the two-component systems in Pseudomonas aeruginosa PAO1.

Authors:  Ying-Tsong Chen; Hwan You Chang; Chin Lung Lu; Hwei-Ling Peng
Journal:  J Mol Evol       Date:  2004-12       Impact factor: 2.395

4.  The lactoperoxidase system links anion transport to host defense in cystic fibrosis.

Authors:  Gregory E Conner; Corinne Wijkstrom-Frei; Scott H Randell; Vania E Fernandez; Matthias Salathe
Journal:  FEBS Lett       Date:  2006-12-19       Impact factor: 4.124

5.  Purification, crystallization and preliminary X-ray crystallographic analysis of the phosphatase domain (PA3346PD) of the response regulator PA3346 from Pseudomonas aeruginosa PAO1.

Authors:  Li Ying Chen; Pei Hsun Wu; Hong Hsiang Guan; Hoong Kun Fun; Hwan You Chang; Chun Jung Chen
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2015-03-20       Impact factor: 1.056

6.  Similarity of gene expression patterns in human alveolar macrophages in response to Pseudomonas aeruginosa and Burkholderia cepacia.

Authors:  Stefan Worgall; Adriana Heguy; Karsta Luettich; Timothy P O'Connor; Ben-Gary Harvey; Luis E N Quadri; Ronald G Crystal
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

7.  AhR sensing of bacterial pigments regulates antibacterial defence.

Authors:  Pedro Moura-Alves; Kellen Faé; Erica Houthuys; Anca Dorhoi; Annika Kreuchwig; Jens Furkert; Nicola Barison; Anne Diehl; Antje Munder; Patricia Constant; Tatsiana Skrahina; Ute Guhlich-Bornhof; Marion Klemm; Anne-Britta Koehler; Silke Bandermann; Christian Goosmann; Hans-Joachim Mollenkopf; Robert Hurwitz; Volker Brinkmann; Simon Fillatreau; Mamadou Daffe; Burkhard Tümmler; Michael Kolbe; Hartmut Oschkinat; Gerd Krause; Stefan H E Kaufmann
Journal:  Nature       Date:  2014-08-13       Impact factor: 49.962

8.  Neutrophil elastase, an innate immunity effector molecule, represses flagellin transcription in Pseudomonas aeruginosa.

Authors:  Avinash Sonawane; Jeevan Jyot; Russell During; Reuben Ramphal
Journal:  Infect Immun       Date:  2006-09-18       Impact factor: 3.441

Review 9.  Adeno-Associated Virus (AAV) gene therapy for cystic fibrosis: current barriers and recent developments.

Authors:  William B Guggino; Liudmila Cebotaru
Journal:  Expert Opin Biol Ther       Date:  2017-07-06       Impact factor: 4.388

10.  Pseudomonas aeruginosa LPS or flagellin are sufficient to activate TLR-dependent signaling in murine alveolar macrophages and airway epithelial cells.

Authors:  Eloïse Raoust; Viviane Balloy; Ignacio Garcia-Verdugo; Lhousseine Touqui; Reuben Ramphal; Michel Chignard
Journal:  PLoS One       Date:  2009-10-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.